Abbott Laboratories $ABT Position Cut by Mesirow Financial Investment Management Inc.

Mesirow Financial Investment Management Inc. trimmed its stake in Abbott Laboratories (NYSE:ABT) by 4.7% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 162,396 shares of the healthcare product maker’s stock after selling 8,028 shares during the quarter. Mesirow Financial Investment Management Inc.’s holdings in Abbott Laboratories were worth $20,346,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in ABT. Invesco Ltd. lifted its stake in Abbott Laboratories by 51.0% in the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after buying an additional 4,713,135 shares during the last quarter. Ninety One UK Ltd bought a new stake in Abbott Laboratories in the fourth quarter valued at $336,815,000. Vanguard Group Inc. lifted its stake in Abbott Laboratories by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 175,556,716 shares of the healthcare product maker’s stock valued at $21,995,501,000 after buying an additional 2,402,408 shares during the last quarter. Alliancebernstein L.P. lifted its stake in Abbott Laboratories by 51.0% in the third quarter. Alliancebernstein L.P. now owns 5,525,906 shares of the healthcare product maker’s stock valued at $740,140,000 after buying an additional 1,865,250 shares during the last quarter. Finally, Capital International Investors lifted its stake in Abbott Laboratories by 2.5% in the third quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock valued at $8,251,974,000 after buying an additional 1,478,076 shares during the last quarter. 75.18% of the stock is currently owned by institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Recent insider-buying coverage highlighted Abbott alongside other companies with insider purchases, which can be interpreted as a sign of confidence from management or executives. Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell (ABT)
• Positive Sentiment: Wall Street sentiment remains relatively constructive, with articles noting that analysts are still broadly optimistic on Abbott and that the stock’s dividend yield has risen to a decade-high level, which may attract value-oriented investors. Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Abbott is also being highlighted in broader healthcare and regenerative-medicine market research, reinforcing that it remains a major player in long-term growth markets, though this is not an immediate stock catalyst. Australia Regenerative Medicine Market Research Trends and Forecasts Report 2026-2035 Featuring Prominent Players Such as Abbott Laboratories, Astellas Pharma, and Roche
• Negative Sentiment: Investors remain focused on Abbott’s post-earnings weakness, including concerns about Exact Sciences dilution, legal risks, and soft diagnostics trends, which have weighed on sentiment and helped keep shares depressed. Abbott Stock at 52-Week Low After Q1 Earnings: Book Profits or Hold?
• Negative Sentiment: Older commentary also pointed to Abbott trading at a low valuation after the Exact Sciences deal and legal judgments, suggesting the market is still discounting uncertainty around earnings quality and integration costs. Abbott’s dividend yield near decade peak, signaling rare buying opportunity

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ABT shares. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price on the stock. in a research note on Wednesday, April 22nd. Royal Bank Of Canada cut their price objective on shares of Abbott Laboratories from $135.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Bank of America cut their price objective on shares of Abbott Laboratories from $150.00 to $120.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Argus cut their price objective on shares of Abbott Laboratories from $140.00 to $125.00 and set a “buy” rating on the stock in a research note on Tuesday, April 21st. Finally, Oppenheimer cut their price objective on shares of Abbott Laboratories from $132.00 to $115.00 and set an “outperform” rating on the stock in a research note on Friday, April 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $119.43.

Insider Transactions at Abbott Laboratories

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the sale, the executive vice president directly owned 104,291 shares in the company, valued at approximately $12,053,953.78. The trade was a 0.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Philip P. Boudreau purchased 2,200 shares of the company’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average price of $91.50 per share, for a total transaction of $201,300.00. Following the completion of the transaction, the chief financial officer owned 2,200 shares of the company’s stock, valued at $201,300. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders sold 3,055 shares of company stock valued at $353,097 in the last quarter. 0.46% of the stock is owned by company insiders.

Abbott Laboratories Price Performance

Shares of NYSE ABT opened at $83.83 on Thursday. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $139.06. The firm’s 50-day simple moving average is $100.17 and its 200 day simple moving average is $113.85. The company has a quick ratio of 1.01, a current ratio of 1.39 and a debt-to-equity ratio of 0.56. The stock has a market cap of $146.02 billion, a P/E ratio of 23.48, a P/E/G ratio of 1.41 and a beta of 0.65.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, April 16th. The healthcare product maker reported $1.15 EPS for the quarter, topping the consensus estimate of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the previous year, the business earned $1.09 earnings per share. Abbott Laboratories’s revenue for the quarter was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Equities analysts expect that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 annualized dividend and a yield of 3.0%. Abbott Laboratories’s payout ratio is 70.59%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.